Osiris Therapeutics, Inc. to Present Advanced Clinical and Scientific Abstracts at Symposium on Advanced Wound Care (SAWC) Fa...
30 Octubre 2018 - 2:30PM
Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine
company focused on developing and marketing products for wound
care, orthopedics, and sports medicine, will present advanced
clinical and scientific research at the Symposium on Advanced Wound
Care (SAWC) Fall Conference. A total of six studies (three clinical
and three scientific studies) will be presented.
The clinical studies highlight the benefits of Osiris's
placenta-based products, Stravix®, Grafix® and GrafixPL®, for use
in covering a variety of wound types. The scientific studies
describe methods of cell viability evaluation in placental tissue
and the structure and properties of tissues preserved using
Osiris’s Prestige Lyotechnologysm, which retain all components of
the native tissue including living cells but can be conveniently
stored at ambient temperature. Key presentations and events
are highlighted below.
Dr. Eric Johnson, MD, will present a lecture entitled
“Scientific and Clinical Evidence for Grafix and GrafixPL:
Cryopreserved and Lyopreserved Placental Membranes” on Friday,
November 2, at 7:30am (Milano V-VI Ballroom, onsite registration
available). Lecture objectives include:
- Information on how placental membranes benefit wound
management
- An overview of how different tissue preservation methods impact
the final composition of placental membrane products
- An introduction to Prestige Lyotechnology for ambient storage
of placental membranes
- Clinical evidence for wound management with Grafix and
GrafixPL
Dr. Charles E. Ananian, DPM, will present a poster summarizing
results of a recently completed multicenter, prospective,
randomized, single-blind trial comparing clinical outcomes and
product cost between Grafix and Dermagraft®(1) in the treatment of
chronic diabetic foot ulcers (DFUs)(2).
Dr. Alexander Reyzelman, DPM, FAPWCA, will present a poster
describing the first prospective cases series evaluating clinical
outcomes of GrafixPL, Osiris’s lyopreserved placental membrane, for
the management of chronic wounds of various etiologies. This study
demonstrates similar closure rates to previous studies utilizing
Grafix, Osiris’s cryopreserved placental membrane, but with
convenience of ambient storage.
Dr. Kathryn Davis, PhD, and Dr. Lawrence Lavery, DPM, MPH, will
present a poster comparing amnion lyophilized by the Prestige
Lyotechnology method (PL) to cryopreserved amnion. Data shows that
the structure and cell viability of PL-lyophilized amnion is
equivalent to those of cryopreserved viable amnion.
Scientific and clinical posters will be presented at the SAWC
fall poster reception from 5:30 pm to 6:15 pm on Saturday, November
3 in the Forum Ballroom, Room 12.
The complete list of scientific and clinical abstracts
includes:
- A Multicenter, Randomized, Single-Blind Trial Comparing the
Efficacy of Viable Cryopreserved Placental Membrane to Human
Fibroblast-Derived Dermal Substitute for the Treatment of Chronic
Diabetic Foot Ulcers (Abstract CR-001)
- A Prospective, Single-Center, Open-Label Case Series Evaluating
the Clinical Outcomes of Viable Lyopreserved Placental Membrane in
the Treatment of Chronic Wounds (Abstract CS-063)
- Contralateral Limb Salvage in a Diabetic Amputee with
Necrotizing Fasciitis: A Case Report Supporting the Use of Viable
Cryopreserved Umbilical Tissue to Prevent Bilateral Amputation
(Abstract CS-080)
- Structure and Cell Viability of Lyophilized Amniotic Membrane
are Equivalent to Those of Cryopreserved Viable Amnion (Abstract
LB-009)
- Structural Properties of Viable Lyophilized Placental Tissues
(Abstract LB-020)
- Assessment of Human Amniotic Tissue Cell Viability (Abstract
LB-028)
Osiris Therapeutics, Inc. will also be exhibiting at the
Symposium on Advanced Wound Care Fall Meeting at booth 321. The
event runs from November 2 through November 4, 2018 at Caesars
Palace in Las Vegas, Nevada.
References:1-Dermagraft® is a registered trademark of
Organogenesis, Inc. (Canton, MA)2-www.clinicaltrials.gov:
NCT02675855
About Osiris Therapeutics
Osiris Therapeutics, Inc., based in Columbia, Maryland,
researches, develops, manufactures and commercializes regenerative
medicine products intended to improve the health and lives of
patients and lower overall healthcare costs. We have achieved
commercial success with products in orthopedics, sports medicine
and wound care, including the Grafix product line, Stravix®, BIO4®
and Cartiform®. We continue to advance our research and
development by focusing on innovation in regenerative medicine,
including the development of bioengineered stem cell and
tissue‑based products. Osiris®, Grafix®, GrafixPL®, GrafixPL
PRIME™ Cartiform®, and Prestige Lyotechnologysm are our trademarks.
BIO4® is a trademark of Howmedica Osteonics Corp., a subsidiary of
Stryker Corporation. More information can be found on the Company’s
website, www.Osiris.com. (OSIR-G)
Forward-Looking Statements
Statements herein relating to the future of Osiris Therapeutics,
Inc. and the ongoing research and development of our products are
forward-looking statements. Osiris Therapeutics, Inc.
cautions that these forward-looking statements are subject to
numerous risks and uncertainties, which could cause actual results
to differ materially from those expressed or implied by such
statements. These risks and uncertainties include those
identified under the heading “Risk Factors” in the Osiris
Therapeutics Inc. Annual Report on Form 10-K for the years ended
December 31, 2017, 2016 and 2015 and Quarterly Report on Form 10-Q
for the quarters ended March 31, 2018 and June 30, 2018, as filed
with the Securities and Exchange Commission (SEC). We caution
investors not to place considerable reliance on the forward-looking
statements contained in this press release. Examples of
forward-looking statements may include, without limitation,
statements regarding the anticipated efficiencies and advantages of
products and the likelihood of customer clinical adoption of any
new products. Although well characterized in scientific
literature and studies, preservation of tissue integrity, including
cells, may not be indicative of clinical outcome.
Accordingly, you should not unduly rely on these forward-looking
statements. You are encouraged to read our filings with the SEC,
available at sec.gov, for a discussion of these and other risks and
uncertainties. The forward-looking statements in this press
release speak only as of the date of this document, and we
undertake no obligation to update or revise any of the
statements. Our business is subject to substantial risks and
uncertainties, including those referenced above. Investors,
potential investors, and others should give careful consideration
to these risks and uncertainties.
For additional information, please
contact:Diane SavoieOsiris Therapeutics, Inc.(443)
545-1834OsirisPR@Osiris.com
Osiris Therapeutics, Inc. (NASDAQ:OSIR)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Osiris Therapeutics, Inc. (NASDAQ:OSIR)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024